论文部分内容阅读
目的探讨经载瘤动脉化疗栓塞(TACE)联合B超引导下射频消融(RFA)综合治疗中晚期肝癌的临床疗效。方法分析81例中晚期肝癌患者的治疗结果,其中36例采用TACE联合B超引导下RFA的综合治疗(综合组),45例仅应用TACE治疗(单纯组),两组皆随访3年,分析比较两组临床获益率及1、2、3年生存率。结果临床获益率(CR+PR+NC)综合组73.30%(26/36),单纯组46.50%(21/45),两组差异有统计学意义(P=0.047)。1、2、3年生存率综合组为94.4%(34/36)、77.8%(28/36)、58.3%(21/36),单纯组为73.3%(33/45)、51.1%(23/45)、24.4%(11/45),两组差异有统计学意义(P<0.05)。结论经载瘤动脉化疗栓塞联合射频消融综合治疗中晚期肝癌疗效肯定,临床获益率高,患者1、2、3年生存率高,是一种有效的联合治疗方法。
Objective To investigate the clinical efficacy of combined radiofrequency ablation (RFA) guided radiofrequency ablation (TRF) combined with TACE and advanced radiotherapy for advanced hepatocellular carcinoma (HCC). Methods Thirty-one patients with advanced hepatocellular carcinoma were treated with TACE combined with B-ultrasound-guided RFA (comprehensive group). 45 patients were treated with TACE alone (single group). All patients were followed up for 3 years. The clinical benefit rate and the 1-, 2-, and 3-year survival rates were compared between the two groups. Results The clinical benefit rate (CR+PR+NC) was 73.30% (26/36) in the comprehensive group and 46.50% (21/45) in the simple group. There was a significant difference between the two groups (P=0.047). The 1-, 2-, and 3-year survival rates for the comprehensive group were 94.4% (34/36), 77.8% (28/36), 58.3% (21/36), and the simple group was 73.3% (33/45), 51.1% (23 /45), 24.4% (11/45), the difference between the two groups was statistically significant (P<0.05). Conclusion The combination of arterial chemoembolization and radiofrequency ablation combined with radiofrequency ablation is effective for the treatment of advanced hepatocellular carcinoma. The clinical benefit rate is high, and the patients have high survival rate at 1, 2 and 3 years. It is an effective combination therapy.